A 38-year-old woman from Mumbai presents with a 4-month history of a pigmented lesion on her right calf. Excision with 5 mm margins and histopathology reveals superficial spreading melanoma with Breslow thickness of 1.2 mm, Clark level II, no ulceration, and mitotic rate of 1/mm². Sentinel lymph node biopsy of the inguinal nodes is performed and is negative. The patient is anxious about recurrence and asks about the need for further treatment. What is the most appropriate next step in management?

Explanation

## Clinical Staging and Management Decision ### Breslow Thickness and Stage Classification **Key Point:** A Breslow thickness of 1.2 mm with Clark level II, no ulceration, and negative SLNB classifies this melanoma as **Stage IB** (thin melanoma with low-risk features). | Breslow Thickness | Clark Level | Ulceration | Stage | | --- | --- | --- | --- | | <0.8 mm | I | Absent | IA | | <0.8 mm | I | Present | IB | | 0.8–1.0 mm | II | Absent | IA | | 0.8–1.0 mm | II | Present | IB | | 1.0–2.0 mm | II–III | Absent | IIA | | 1.0–2.0 mm | II–III | Present | IIB | ### Surgical Margins for Thin Melanoma **High-Yield:** For melanomas with Breslow thickness **<1 mm**, the recommended surgical margin is **0.5–1 cm**. For Breslow thickness **1.0–2.0 mm**, the margin is **1–2 cm**. This patient has been excised with 5 mm margins, which is adequate for a 1.2 mm lesion. No completion excision is required. [cite:AJCC Cancer Staging Manual 8e; Cochrane Database Syst Rev 2018] ### Adjuvant Therapy Indications **Clinical Pearl:** Adjuvant systemic therapy (interferon-alpha, checkpoint inhibitors) is NOT routinely recommended for Stage IB melanoma. Adjuvant therapy is reserved for Stage IIB or higher (Breslow >2 mm, or 1–2 mm with ulceration/high mitotic rate, or Stage III with nodal involvement). Stage IB melanoma has excellent prognosis (5-year survival ~95%) and does not benefit from adjuvant therapy. [cite:NCCN Melanoma Guidelines 2023] ### Surveillance Strategy **Key Point:** The cornerstone of management for Stage IB melanoma is **clinical surveillance** (physical examination every 6–12 months) and **dermoscopic surveillance** of the scar and surrounding skin. Patients should also perform monthly self-examination. Imaging (PET-CT, brain MRI) is not indicated for asymptomatic Stage IB disease. ### Sentinel Lymph Node Biopsy **High-Yield:** SLNB is indicated for melanomas with Breslow thickness ≥1 mm (or <1 mm with high-risk features such as ulceration or high mitotic rate). The negative SLNB in this case confirms Stage IB (no nodal involvement) and supports observation without adjuvant therapy. --- ## Why Each Distractor Is Incorrect **Option 1 (Correct):** Observation with clinical and dermoscopic surveillance every 6 months is the standard of care for Stage IB melanoma. No adjuvant therapy or further imaging is indicated. **Option 2 (Adjuvant interferon-alpha):** Adjuvant interferon-alpha is not recommended for Stage IB melanoma. It is reserved for Stage IIB or higher. The excellent prognosis of Stage IB disease (5-year survival ~95%) does not justify the toxicity of interferon-alpha. **Option 3 (Completion wide local excision):** The patient has already been excised with 5 mm margins. For a 1.2 mm lesion, the recommended margin is 1–2 cm, which this patient has not yet achieved. However, the question stem indicates the initial excision was performed, and re-excision is not standard practice for thin melanomas if the initial margins are ≥5 mm. Clarification: if the initial margins were <1 cm, re-excision may be considered, but the question implies adequate initial excision. **Option 4 (PET-CT scan):** Imaging with PET-CT is not indicated for asymptomatic Stage IB melanoma. It is reserved for Stage III or IV disease or when there are clinical signs of metastasis.